Hims & Hers Health (NYSE:HIMS) Given New $35.00 Price Target at Barclays

Hims & Hers Health (NYSE:HIMS) had its target price cut by investment analysts at Barclays from $39.00 to $35.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 5.17% from the company’s previous close.

Other analysts have also recently issued research reports about the company. JPMorgan Chase & Co. lowered their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Canaccord Genuity Group boosted their price target on Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Truist Financial lifted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Morgan Stanley lifted their target price on shares of Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Four investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average price target of $32.17.

Hims & Hers Health Trading Up 4.5%

HIMS traded up $1.42 on Friday, hitting $33.28. 3,523,938 shares of the company were exchanged, compared to its average volume of 26,096,568. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $65.30. The stock has a market capitalization of $7.76 billion, a PE ratio of -52.83 and a beta of 2.40. The firm has a fifty day simple moving average of $32.23 and a two-hundred day simple moving average of $26.09. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same quarter last year, the company earned $0.17 EPS. Hims & Hers Health’s revenue for the quarter was up 38.2% on a year-over-year basis. Sell-side analysts expect that Hims & Hers Health will post -0.05 earnings per share for the current year.

Insider Activity

In other news, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total transaction of $830,410.00. Following the completion of the transaction, the insider directly owned 181,861 shares of the company’s stock, valued at approximately $6,365,135. This represents a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 4,938 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $29.99, for a total transaction of $148,090.62. Following the completion of the transaction, the chief financial officer owned 264,117 shares of the company’s stock, valued at approximately $7,920,868.83. The trade was a 1.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 186,769 shares of company stock worth $6,035,648 over the last quarter. Corporate insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after purchasing an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health in the first quarter worth about $30,000. EverSource Wealth Advisors LLC boosted its position in shares of Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares during the period. Amundi grew its position in shares of Hims & Hers Health by 5.3% during the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after buying an additional 522 shares during the period. Finally, California Public Employees Retirement System grew its position in shares of Hims & Hers Health by 9.5% in the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after purchasing an additional 29,471 shares during the period. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.